Timothy Craven
CEO, Insamo
Integrating computational design and display screening for ultra high-throughput cell-permeable cyclic peptide discovery.
Company Description
Pioneering the discovery of membrane-permeable and orally-available cyclic-peptides with antibody-like binding affinity.
Bio
I am the co-founder and CEO of Insamo. Prior to founding Insamo, I completed a postdoctoral fellowship and earned an MBA while working with David Baker at the University of Washington. I earned my PhD at NYU, where I worked with Rich Bonneau (now Head of AI Molecular Design at Genentech) and Kent Kirshenbaum. Before graduate school, I held research positions at NASA, NIST, the FDA, and Merck.